Skip to main
VTRS

Viatris (VTRS) Stock Forecast & Price Target

Viatris (VTRS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Viatris is also focusing on expanding its presence in key therapeutic areas, such as dermatology, ophthalmology, and gastroenterology, which show potential for growth. With its strong portfolio of both generic and legacy drugs and a global reach of over 165 countries, Viatris is well-positioned for continued success in the pharmaceutical industry.

Bears say

Viatris is facing challenges with its fragmented portfolio and declining sales due to the loss of patent exclusivity for key drugs like Lipitor and Viagra. Additionally, its merger with Mylan has not resulted in significant cost savings or increased efficiency. The highly competitive generics market and potential delays or failures in the pipeline development of selatogrel could hinder their future growth.

Viatris (VTRS) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viatris (VTRS) Forecast

Analysts have given Viatris (VTRS) a Buy based on their latest research and market trends.

According to 6 analysts, Viatris (VTRS) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viatris (VTRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.